Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

mAb Biosimilars Market Size, Share, Strategies, Insights and Forecasts To 2020

Thursday, October 6, 2016 22:29
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Technavio Announces the Publication of its Research Report Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Monoclonal Antibody (mAb) Biosimilars Market: Biocon, Celltrion, Dr. Reddy’s Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.

Browse full report with TOC@

Commenting on the report, an analyst from Technavios team said: One trend spurring growth is the emergence of biosimilars. At present, it has been observed that due to the increase in geriatric population, the prevalence of chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers, and metabolic disorders, has increased. As a result, Biosimilars will play a major role in this scenario. The increased sales of biosimilars are expected to pull down the sales of biologics during the forecast period.”

According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries. A biosimilar can be developed only after the patent expiry of the original product . Many first-generation biopharmaceuticals have expired or will expire during the forecast period. For instance, the patent of drugs such as Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis are expected to expire during the forecast period.

Further, the report states that a major challenge for this market is the physicians’ reluctance to prescribe biosimilars. Physicians are reluctant to prescribe biosimilars to patients, as mAbs cannot be substituted with these drugs. mAbs are developed using a living system or a genetically modified organism. Any minute variation in the entire process will have adverse effects on the safety and effectiveness of the final product. Biosimilars can also not be used during post-marketing surveillance as the substitution of drugs is prohibited during this period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. 

Request A Sample copy of This Report @

About Biosimilars

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

Technavios analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.

Covered in this report 

The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography: 

Technavio’s report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

To Get Discount On The Report @

Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.